NervGen Reports Strong Phase 1b/2a Gait Analysis Data for NVG-291, Showing Neural Recovery
Summary
NervGen Pharma announced positive Phase 1b/2a clinical trial results for its lead candidate NVG-291, demonstrating statistically significant neural recovery in spinal cord injury patients.
Key Events
-
Positive Phase 1b/2a Clinical Data
NVG-291 demonstrated a statistically significant treatment effect (p=0.0197) in biomechanical gait analyses for chronic spinal cord injury.
-
Evidence of Genuine Neural Recovery
The analyses showed improvements in coordination, mechanical effort, and postural stability, indicating true neural recovery rather than compensatory effort.
-
High Responder Rate
100% (10/10) of NVG-291 subjects were classified as responders across composite recovery measures, compared to just 10% (1/10) of placebo subjects (p=0.0001).
-
Supports Phase 3 Advancement
These results reinforce the foundation for the upcoming Phase 3 RESTORE registrational study, for which FDA alignment was previously secured.
Analysis
This filing details highly positive biomechanical gait analysis results for NervGen's lead drug candidate, NVG-291, in chronic spinal cord injury. The statistically significant improvements in coordination, mechanical effort, and postural stability provide objective evidence of genuine neural recovery, not just compensation. This data is critical for the company, especially following recent 'going concern' warnings and a capital raise, as it de-risks the program and strengthens the rationale for the upcoming Phase 3 RESTORE study.
At the time of this filing, NGEN was trading at $2.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $172.4M. The 52-week trading range was $1.98 to $6.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.